Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101

This study has been completed.
Information provided by:
Baxalta US Inc. Identifier:
First received: September 8, 2005
Last updated: June 26, 2015
Last verified: July 2013
The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of children with hemophilia A. The study is open to pediatric patients in Canada who completed Baxter Study 060101.

Condition Intervention Phase
Hemophilia A
Drug: Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (ADVATE rAHF-PFM): Safety Monitoring in Pediatric Patients Diagnosed With Severe to Moderately Severe Hemophilia A - A Continuation of Baxter Clinical Study 060101

Resource links provided by NLM:

Further study details as provided by Baxalta US Inc.:

Primary Outcome Measures:
  • Assessment of safety, as measured by the incidence, causality, and severity of adverse experiences

Secondary Outcome Measures:
  • Assessment of the hemostatic efficacy in the treatment of bleeding episodes;
  • assessment of the hemostatic efficacy in surgical or invasive procedures

Enrollment: 4
Study Start Date: December 2004
Study Completion Date: November 2006
Intervention Details:
    Drug: Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)

    Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator). Once the treatment regimen was established, the regimen was to be maintained for the duration of the study, unless clinical reasons necessitated a change.

    The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.


Ages Eligible for Study:   up to 6 Years   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must have participated and completed participation in Baxter's clinical study 060101
  • Subject or parent/legally authorized representative has provided written informed consent

Exclusion Criteria:

  • Subjects who have withdrawn from Baxter's Clinical Study 060101 prior to the termination of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00189982

Canada, Ontario
Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1X8
Sponsors and Collaborators
Baxalta US Inc.
Principal Investigator: Victor Blanchette, MD Hospital for Sick Children, Division of Hematology/Oncology, Toronto, Canada
  More Information Identifier: NCT00189982     History of Changes
Other Study ID Numbers: 060401
Study First Received: September 8, 2005
Last Updated: June 26, 2015

Keywords provided by Baxalta US Inc.:
Factor VIII Deficiency

Additional relevant MeSH terms:
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Factor VIII
Coagulants processed this record on May 22, 2017